SEC Filings
Medpace's Three Book-To-Bill Shareholder Suits Are Dropped, Then A $1 Billion Buyback Is Approved
Plaintiffs withdrew all three suits without prejudice as the board replaced its repurchase authorization, Medpace's 10-Q shows.
Medpace Holdings (MEDP) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Plaintiffs withdrew all three suits without prejudice as the board replaced its repurchase authorization, Medpace's 10-Q shows.
Earnings
The trial-services firm posted record new awards but would not give a 2027 outlook, citing cancellations and a $20 million Cincinnati cost.
Earnings
The clinical research firm's revenue, new awards and backlog all grew, and a repurchase plan running through 2028 replaces the old one.
Insider Trades
A Form 4 filed Thursday covers 48,667 shares sold across two days, the sixth such filing in roughly two weeks.